### **Company Profile** - **Name:** Fischer Medical Ventures Limited (FMVL) - **Former Name:** Fischer Chemic Limited - **Incorporation:** 1993 - **Headquarters:** Chennai, Tamil Nadu, India - **Manufacturing Facility:** Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam - **BSE/NSE Ticker:** FISCHER - **Corporate Identity Number (CIN):** L86900AP1993PLC118162 FMVL is a publicly listed, deep-tech MedTech company focused on indigenously manufacturing advanced diagnostic imaging technologies, digital health platforms, and preventive healthcare solutions. Since rebranding in March 2024, it has pivoted from chemical manufacturing to become a leader in AI-powered medical technology and "Make in India" medical innovation. --- ### **Core Business Segments** Fischer Medical Ventures operates through two primary verticals: #### **1. Diagnostic Imaging & Medical Equipment** - **Flagship Products:** 0.35T PICA (Open MRI), 1.5T MICA & QUIN (Whole-Body MRI), NEONA (Neonatal MRI), NOVA (7–9.4T Preclinical MRI), EMMA (Breast MRI), VEGA (Low-Field TOF MRI), and upcoming CT scan systems. - **Key Technology Partnerships:** Dr. Iype Cherian (Neurosurgeon), Time Medical International Ventures (India) Pvt Ltd (Wholly Owned Subsidiary). - **Indigenous Manufacturing:** First and only company in India to manufacture FDA- and CE-compliant MRI systems domestically at AMTZ. - **CT Expansion:** Developing CT systems (CT 16 to CT 128) with AI-enhanced imaging, low-dose acquisition, self-adaptive noise reduction, and holographic dynamic technology. - **Portable X-ray Systems:** Launched handheld, AI-integrated digital X-ray devices for chest/lung imaging and TB screening—lightweight (<3 kg), low-radiation, and ideal for rural deployments. #### **2. Preventive Healthcare & Digital Health Ecosystem** - **Brand:** FlynnCare – AI-powered preventive health platforms. - **Platform:** eHAP (e-Health Access Point) and Health Kiosks offering 50+ clinical parameter measurements (cardio, respiratory, mental, eye, oral, women’s health, etc.). - **Tele-Diagnosis Network:** Integrated tele-radiology and remote specialist access via LIVE Dx and MIDAS platforms. - **AI Solutions:** Scalable AI-driven screening for cancer, TB, mental health (vocal biomarkers), and pre-diabetes (non-invasive HbA1c from facial scans). - **Awards:** FlynnCare received the Silver Award at ARCA 2025, recognizing its contributions to affordable preventive healthcare and Indian innovation. --- ### **Strategic Subsidiaries & Joint Ventures** | Entity | Ownership | Focus | |-------|----------|-------| | **Time Medical International Ventures (India) Pvt Ltd (TMIV)** | 100% | MRI design & manufacturing; India’s first indigenous MRI maker (CDSCO certified) | | **FMV International Ventures Pte Ltd** | 100% | Singapore-based subsidiary for Southeast Asia expansion | | **FlynnCare Health Innovations (FCHI)** | 100% | AI/HealthTech platform development (e.g., ATLAS, Clinics 2.0) | | **DigiHealth Specialists Inc.** | Substantially Owned | Telehealth and diagnostic kiosks in the Philippines | | **Nanomedic Technologies Ltd** | Portfolio Company | Advanced wound care: SpinCare® (spray-on regenerative skin matrix) | | **NYB.AI** | Strategic Partner | AI-powered drug discovery using graph neural networks and natural compound libraries | --- ### **Key Innovations & Product Highlights** | Product | Key Features | Applications | |--------|-------------|------------| | **PICA (0.35T Open MRI)** | Open design, cryogen-free, low power (40% less than conventional), no helium dependency, teleradiology built-in | Musculoskeletal, neurology, pediatric imaging; ideal for rural/tier-2/3 clinics | | **QUIN (1.5T Helium-Free MRI)** | Eliminates liquid helium refills, high slew rate (258 T/m/s), reduced operating costs by 20–25% | High-resolution soft tissue diagnostics | | **NEONA (1.5T Neonatal MRI)** | World’s first neonatal MRI; 50–70% lower RF exposure, 80% noise reduction, designed for NICUs | Neonatal brain and body imaging | | **MICA (1.5T Whole-Body MRI)** | HTS technology, image quality comparable to 3T, remote diagnostics, fast scanning | Broad clinical use; integrates AI for scan acceleration and auto-reads | | **EMMA (Breast MRI)** | Abbreviated protocol, 70% faster than standard MRI, radiation-free, AI-aided diagnosis | Early detection in dense breast tissue; FDA approved | | **VEGA (Low-Field TOF MRI)** | Permanent magnet, no helium, no contrast agents, 6-minute brain scan | Population-level screening for unruptured aneurysms in district hospitals | | **DRIS-iMRI Medharanya** | Intraoperative MRI with AR, AI, ML, exoscope integration | Real-time imaging during neurosurgery; supports guided tumor resection | | **Obelab & MONA** | Portable brain imaging & low-field MRI with AI for mental health and MSK imaging | Point-of-care diagnosis, elderly and anxious patients | --- ### **Global & Domestic Expansion** - **Revenue Model:** Mix of outright sales (preferred OEM model) and leasing (e.g., Sikkim Govt. MOU). - **Manufacturing Capacity:** 160 MRI units/year at AMTZ facility; plans to scale CT production in India. - **International Markets:** USA, Singapore, ASEAN, Philippines, Malaysia, Indonesia, Middle East, Africa. - **Strategic Hubs:** - **Malaysia:** Acquired landmark property in Malacca to build an Integrated Regional Healthcare Hub. - **Indonesia:** Public-private partnership with Jember City under "TB Free by 2026" initiative using AI-X-ray and tracking systems. - **Philippines:** Supplying 65 digital X-ray units to Tamil Nadu Animal Husbandry; deploying DigiHealth ATM kiosks. --- ### **Partnerships & Collaborations** | Partner | Focus | |--------|-------| | **Dr. Iype Cherian** | Development of DRIS-iMRI Medharanya (intraoperative MRI) | | **Nanyang Biologics (NYB.AI)** | AI-driven discovery of nutraceuticals from Indian/Southeast Asian herbs | | **Nervotec Pte Ltd** | Contactless vital monitoring via smartphone camera (HbA1c, BP, hemoglobin, stress) | | **The Therapy Platform** | AI-enhanced online counseling and mental health therapy | | **BluSim Tech** | AI-powered, contactless monitoring for elderly care (bed-based ballistocardiography) | | **TAG (India’s largest EdTech provider)** | National school health screening across 30,000+ schools | | **DoctorOnCall (Malaysia)** | Integrated telehealth, e-pharmacy, and insurance ecosystem | --- ### **Sustainability & Social Impact** - **Helium-Free Technology:** Eliminates supply chain risks and environmental hazards associated with liquid helium. - **Energy Efficiency:** PICA and VEGA reduce power consumption by up to 40%. - **Rural Healthcare Access:** Deployed in off-grid areas; suitable for unstable power environments. - **TB Control:** Entered TB eradication market via handheld X-ray and molecular kits; aligned with Indonesia’s Presidential Regulation 67/2021. - **Animal Health:** Partnered with BAV to commercialize intranasal STVAC vaccine for goats/sheep, reducing mortality to <5%. --- ### **AI & Digital Health Platforms** | Platform | Function | |--------|---------| | **ATLAS** | Containerized hybrid cloud platform with big data analytics and “One Patient = One Document” unification | | **MIDAS** | AI-powered multispectral analysis and clinical decision support | | **Clinics 2.0** | Scalable EHR/HIS for clinics and hospitals | | **LIVE Dx** | Real-time tele-diagnosis, teleradiology, and remote consultation | --- ### **Recent Milestones (2024–2025)** - Achieved ₹100-crore revenue within two years of full operations. - Launched India’s first ISO-certified, Made-in-India MRI systems. - Supplied 65 digital X-ray units to Tamil Nadu for veterinary healthcare modernization. - Secured national school health screening contract covering 30,000+ schools. - Entered Arab Health 2025 with strong international traction. - Received NHS UK registration for SpinCare®, now approved in 34 countries. - FDA submission for SpinCare® underway (expected Q4 2025). --- ### **Corporate Strategy** Fischer Medical Ventures is positioning itself as a transformative force in **affordable, accessible, and AI-integrated healthcare**, with: - A focus on **preventive care** (e.g., cancer, TB, mental health screening). - Expansion into **comprehensive diagnostic ecosystems** (MRI → CT → X-ray → AI + SaaS platforms). - Strategic investments in **biologics, drug discovery, and elderly/mental health tech**. - Commitment to **"Make in India"** and **"Aatmanirbhar Bharat"** in high-end MedTech. FMVL aims to transition from a hardware manufacturer to a **global platform company**, delivering **end-to-end diagnostic, preventive, and therapeutic solutions**—all powered by AI, sustainability, and indigenous innovation.